Hengrui Medicine (600276.SH): Three drugs including HRS-6209 capsules approved for clinical trials.

Zh tng cijng APP xn, hng ru yyo (600276.SH) fb gnggo, jnr, gngs j zgngs shndng shngd yyo yuxin gngs, gungdng hng ru yyo yuxin gngs shudo guji yopn jind gunl j hzh qng f guny HRS-6209 jionng, HRS-8080 pin, HRS-9813 jionng de yow lnchu shyn p zhn tngzh shjing y jnq kizhn lnchu shyn. Intelligent Financial APP News, Hengrui Medicine (600276.SH) announced that recently, the company and its subsidiaries Shandong Shengdi Pharmaceutical Co., Ltd. and Guangdong Hengrui Pharmaceutical Co., Ltd. received the approval notification issued by the National Medical Products Administration for the clinical trial of HRS-6209 capsules, HRS-8080 tablets, and HRS-9813 capsules, and will conduct clinical trials in the near future.